📰 Objective Response Rate News
Objective Response Rate News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Objective Response Rate. Real-time updates on events, politics, business and more.
May 24, 2024
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months) and overall survival (median 14.3 months) support continued development of mitazalimab in a randomized confir...
May 24, 2024
Alligator Bioscience AB announced that two clinical abstracts on its lead drug candidate mitazalimab, a best- in-class CD40 agonist, in first line metastatic pancreatic cancer will be presented in a...
May 23, 2024
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months)
May 20, 2024
First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20...
May 17, 2024
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor
May 16, 2024
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the...
April 30, 2024
/PRNewswire/ -- Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the...
April 30, 2024
STOCKHOLM, April 30, 2024 /PRNewswire/ — Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months. January – March Financial summary for the quarter Net turnover amounted to […]
April 10, 2024
Investegate announcements from AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
April 10, 2024
OCALA, Fla., April 10, 2024 -- AIM ImmunoTech Inc. today announced top-line interim data indicating that combining Ampligen with Keytruda in the treatment of recurrent ovarian cancer may have...